Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;9(10):1285-1290.
doi: 10.1111/1759-7714.12836. Epub 2018 Aug 20.

Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy

Zui Liu  1 , Wei Ou  1 , Ning Li  2 , Si-Yu Wang  1
Affiliations

Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy

Zui Liu et al. Thorac Cancer. 2018 Oct.

Abstract

Background: Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), has proven to be effective and safe for treating patients with advanced gastric cancer after second-line chemotherapy failure. As VEGFR-2 targeted therapy has made encouraging progress for the treatment of a broad range of malignancies, we explored the efficacy and safety of apatinib for the treatment of advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.

Methods: We retrospectively analyzed the data of 34 patients (11 with squamous carcinoma and 23 with adenocarcinoma) who were treated with apatinib alone in a daily oral dose of 250 mg in the second-line or third-line setting from January 2016 to July 2017. The primary endpoint was progression-free survival (PFS).

Results: EGFR mutation or amplification was detected in 15 patients. The median PFS of the whole group was four months (95% confidence interval 0.3-7.7). A partial response was observed in 2 patients (5.88%) and stable disease in 19 (55.88%). The disease control rate was 61.76%. Common side effects of apatinib were hypertension (n = 12), hand-foot syndrome (n = 8), and proteinuria (n = 5), which accounted for 35.30%, 23.53%, and 14.71%, respectively, and no grade 3/4 adverse reactions occurred. Apatinib toxicity was controllable and tolerable.

Conclusions: Apatinib appears to be effective and safe for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.

Keywords: Anti-VEGF; apatinib; efficacy; non-small cell lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier estimates of progression‐free survival.
Figure 2
Figure 2
Waterfall plot of measurable lesion response.
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108. - PubMed
    1. Zhi XY, Zou XN, Hu M, Jiang Y, Jia MM, Yang GH. Increased lung cancer mortality rates in the Chinese population from 1973–1975 to 2004–2005: An adverse health effect from exposure to smoking. Cancer 2015; 121 ((Suppl 17)): 3107–12. - PubMed
    1. Chen WQ, Zheng RS, Baade PD et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32. - PubMed
    1. Maemondo M, Inoue A, Kobayashi K et al Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380–8. - PubMed
    1. Mitsudomi T, Morita S, Yatabe Y et al Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–8. - PubMed